Erich Tauber is co-founder and has been CEO of Themis since its inception in 2009.
He has been working in the pharmaceutical and biotechnology industry since 2000 and has served in various roles with increasing responsibilities at AstraZeneca, Baxter, Intercell and Nycomed. In particular, he was responsible for the development and commercialization of Ixario, the first Japanese Encephalitis vaccine. He is a renowned expert in the field of vaccine and product development and a frequent author of scientific publications and speaker at corporate conventions.
He received his medical training at the University of Vienna and holds a medical Doctorate from the Medical University in Vienna. Before joining the industry, he was a pediatric research fellow at the Vienna University Children’s Hospital and the Southampton Children’s Hospital, UK.
Dr. Philippe Dro is currently chairman, chief executive officer and director of the board at Luciole Medical (Zürich, Switzerland), CHAIRMAN OF LIMMATECH BIOLOGICS (ZÜRICH SWITZERLAND), member of the board at Themis Bioscience GmbH, (Austria) as well as Omics SA Bioinformatics (France), a BIOINFORMATIC COMPANY. He WAS CEO AND DIRECTOR at Glycovaxyn AG (ZÜRICH, Switzerland) WHICH WAS ACQUIRED BY GSK IN 2015. HE SERVED IN THE BOARD OF Aleva Therapeutics SA (Switzerland), Spinevision SA (France), Antares Pharma Ltd (USA), and SkyePharma Ltd (USA). Dr. Philippe Dro ALSO served as a chairman and chief executive officer at ENDOART SA (Lausanne, Switzerland) ACQUIRED BY ALLERGAN IN 2007 AND as a chief financial officer/chief operating officer at Axovan AG (Basel, Switzerland), and president & chief operating officer. He has a PHARMD FROM GRENOBLE SCHOOL OF PHARMACY (FRANCE) and a MBA both from Ecole Supérieure de Commerce de Lyon (France) and Cranfield School of Management (UK).
Dr. Smith is a biopharmaceutical CMC and process development expert who, over the course of his career, advised a broad range of small to large biotech and pharmaceutical companies globally. He specializes in the CMC aspects of medical product development covering vaccines, therapeutics and diagnostics working with researchers and product developers through to manufacturing. Prior to joining Themis as CTO, he founded GreyRigge Associates in 2010, a consulting firm focused on providing both technical and commercial expertise for the biopharmaceutical development process to his clients. Dr. Smith held a number of senior roles internationally in companies including SingVax, Davos Life Science, Emergent Biosolutions and GlaxoSmithKline. He holds Doctorate and Bachelor degrees in biochemistry from the University of Bath and University of West England, Bristol, respectively.
Katrin Ramsauer joined Themis in 2010 as Senior Scientist Vaccine Development. Since 2013 she heads Themis preclinical and clinical development advancing the companies lead program in Chikungunya through a successful Phase 1 study. Prior to Themis she was a postdoctoral scientist at Novartis Vaccine and Diagnostics Inc. in Cambridge, MA where she investigated the mechanisms of action of vaccine candidates and small molecule compounds.
Dr. Ramsauer also held postdoctoral fellowship positions at the Clinical Institute of Virology, Medical University of Vienna and Max F. Perutz Laboratories, University of Vienna. She holds a PhD in molecular biology and immunology and a Master in microbiology from the University of Vienna.
David A. Maier joined Themis in 2015 to direct all financial matters for the company. Mr. Maier started his career at a Big 4 audit firm and thereafter managed a local private equity fund in Austria and held several positions on the supervisory board level at portfolio companies. Beside his finance position at Themis, he is specialized in company valuation and acts as an expert witness in this field.
Additionally, he is a lecturer at the University of Applied Science (FH Wien) and publishes specialist articles concerning valuation and finance. He attended a chemical technical college and studied business administration at WU Wien with focus on finance and controlling.
Dr. Mandl is an internationally renowned expert on arboviruses with over 25 years of experience in vaccine development. He previously served as Global Head of Research, Early and Exploratory Clinical Development at Novartis Vaccines where he directed a team of over 300 employees working on more than 15 viral and bacterial vaccine pipeline projects and platform technologies.
Prior to Novartis, he acted as Professor and Deputy Head of the Department of Virology at the Medical University of Vienna. Dr. Mandl received his M.D. and Ph.D. from the University of Vienna and his M.S. in biochemistry from Pennsylvania State University.
Alexander Kort is SVP Corporate Development at Themis Bioscience GmbH in Vienna, Austria. His responsibilities include all business development and licensing activities of Themis and oversight of all internal corporate development activities. Alexander has more than 10 years’ experience in the vaccine industry from vaccine development to vaccine manufacturing.
Prior to Themis Alexander held various positions with increasing responsibility in project management, process development and manufacturing and strategic operations at IDT Biologika GmbH, a global vaccines and biologics CDMO. Alexander graduated in Biosystems Engineering and holds an IPMA certificate for Project Management.
Matthias Müllner has been leading Themis CMC efforts since 2013, developing a scalable and robust manufacturing process. He joined Themis in 2011 as Senior Scientist Vaccine development from the Children’s Cancer Research Institute (CCRI), Vienna. In his postdoctoral scientist position he developed treatments against adenoviral infections of immunocompromised patients.
He is a lecturer at the university of applied science (FH Wien) and holds a PhD and a Master in molecular biology from the University of Vienna.
Jochen Stritzker joined Themis as Senior Vice President Immunotherapy in January 2019. With more than 15 years in immuno-oncology, he has gained experience in transitioning product candidates from discovery research to advanced clinical trials.
Prior to Themis, Jochen held various positions with increasing responsibility at Genelux Corporation. In his most recent role he led the company’s discovery, preclinical as well as clinical trial-supporting translational research using oncolytic viruses and various therapeutic approaches that take advantage of combination strategies. Moreover, he was engaged in business development activities.
Dr. Stritzker received his PhD in microbiology at the University of Würzburg in
Germany, where he also successfully obtained his habilitation.
Dr. Monika Mangold joined Themis in October 2019. In her role as Head of Project Management she leads the Project Management team and is responsible for the management of the company´s product development projects.
Prior to Themis, Monika had various R&D Project Lead and Project Management positions in the bio pharma industry and was responsible for project- and portfolio management across the whole product development life cycle from preclinical- to licensure phase.
She brings approximately 15 years of experience in global product development in a wide range of therapeutic areas, including tissue regeneration, cardiology and hematology & oncology.
Monika holds a PhD in Microbiology and Genetics from the University of Vienna.